These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 20143002)
1. [TNF-alpha and insulin-resistance: metabolic effects of in vivo therapeutic blockade]. Ursini F Reumatismo; 2009; 61(4):254-9. PubMed ID: 20143002 [TBL] [Abstract][Full Text] [Related]
14. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Gonzalez-Gay MA; Gonzalez-Juanatey C; Vazquez-Rodriguez TR; Miranda-Filloy JA; Llorca J Ann N Y Acad Sci; 2010 Apr; 1193():153-9. PubMed ID: 20398022 [TBL] [Abstract][Full Text] [Related]
15. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Collamer AN; Battafarano DF Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412 [TBL] [Abstract][Full Text] [Related]
16. Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation. Couriel DR; Hicks K; Giralt S; Champlin RE Curr Opin Oncol; 2000 Nov; 12(6):582-7. PubMed ID: 11085458 [TBL] [Abstract][Full Text] [Related]
17. Tumor Necrosis Factor-Alpha: Role in Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Mellitus. Akash MSH; Rehman K; Liaqat A J Cell Biochem; 2018 Jan; 119(1):105-110. PubMed ID: 28569437 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of infliximab in inflammatory bowel disease. Hurd LB; Lichtenstein GR Gastroenterol Nurs; 1999; 22(5):199-208. PubMed ID: 10776108 [TBL] [Abstract][Full Text] [Related]
19. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. Zinman B; Hanley AJ; Harris SB; Kwan J; Fantus IG J Clin Endocrinol Metab; 1999 Jan; 84(1):272-8. PubMed ID: 9920095 [TBL] [Abstract][Full Text] [Related]
20. Sudden progression from impaired glucose tolerance to type 2 diabetes after discontinuation of administration of anti-tumor necrosis factor-alpha antibody infliximab. Ursini F; Succurro E; Grembiale A; Rudi S; Grembiale RD; Arturi F Int J Immunopathol Pharmacol; 2010; 23(3):961-3. PubMed ID: 20943070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]